SecBot SecBot
SECBOTREPLAY Home › Report › VTGN

VTGN · Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol for…

Vistagen Therapeutics, Inc. · 8-K filed Jun 30, 2026 at 08:28 ET

At the news

BEARISHIMPACT 7/10

8-K filed Jun 30, 2026 at 08:28 ET

Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder failed to meet the primary endpoint (p=0.427) and secondary endpoints in the overall population. A post-hoc analysis showed nominal statistical significance in a subgroup of patients with very severe social anxiety (p=0.036), but this is exploratory and not confirmatory. The company plans to meet with the FDA to discuss a potential registrational pathway involving a single future Phase 3 trial, but the lead program's path to approval is now highly uncertain, representing a material negative catalyst for this $10M market cap biotech.

  • PALISADE-4 Phase 3 trial of fasedienol failed to meet the primary endpoint (p=0.427) and secondary endpoints in the overall population (n=238).
  • Fasedienol LS mean SUDS change was -9.5 vs placebo -11.4, difference 1.9 (p=0.427), not statistically significant.
  • A post-hoc analysis in a subgroup with very severe SAD (n=123) showed nominal statistical significance (p=0.036), but this is exploratory and not confirmatory.
  • Company plans to meet with FDA to discuss a potential registrational pathway involving a single future multi-dose Phase 3 trial with LSAS as primary endpoint, using prior PALISADE-2 data as confirmatory evidence.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access